Page last updated: 2024-11-03

ag 1879 and Leukemia, Erythroblastic, Acute

ag 1879 has been researched along with Leukemia, Erythroblastic, Acute in 2 studies

3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor

Leukemia, Erythroblastic, Acute: A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wilson, MB1
Schreiner, SJ1
Choi, HJ1
Kamens, J1
Smithgall, TE1
Kosmider, O1
Denis, N1
Lacout, C1
Vainchenker, W1
Dubreuil, P1
Moreau-Gachelin, F1

Other Studies

2 other studies available for ag 1879 and Leukemia, Erythroblastic, Acute

ArticleYear
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Oncogene, 2002, Nov-21, Volume: 21, Issue:53

    Topics: Apoptosis; Cell Division; Cell Transformation, Neoplastic; DNA-Binding Proteins; Dose-Response Relat

2002
Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.
    Cancer cell, 2005, Volume: 8, Issue:6

    Topics: Animals; Benzamides; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Disease Progression

2005